Literature DB >> 18521317

Imaging of Primitive Neuroectodermal Tumor (PNET) by Technetium-99m Tetrofosmin.

G Karanikas1, W Köstler, A Becherer, R Dudczak, M Krainer, K Kletter.   

Abstract

Purpose. Tc-99m tetrofosmin launched for myocardial studies has recently also shown a good detectability for several tumors. Data on PNET imaging by Tc-99m tetrofosmin are not yet available.Patient and method. In the case of a 21-year-old man suffering from pelvis PNET, Tc-99m tetrofosmin scintigraphy was performed additionally to CT and MRI.Results. The gluteal and iliac tumor masses were visualized by Tc-99m tetrofosmin according to the CT and MRI results.Discussion. Imaging with Tc-99m tetrofosmin could provide additional information to the available conventional radiological imaging modalities for diagnosis of PNET, and could be a useful tool for the restaging of the primary tumor.

Entities:  

Year:  2001        PMID: 18521317      PMCID: PMC2395460          DOI: 10.1080/13577140120099218

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  3 in total

1.  Benign versus malignant breast disease: comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography.

Authors:  H M Fenlon; N C Phelan; P O'Sullivan; S Tierney; T Gorey; J T Ennis
Journal:  Radiology       Date:  1997-10       Impact factor: 11.105

2.  Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas.

Authors:  V Söderlund; C Jonsson; H C Bauer; O Brosjö; H Jacobsson
Journal:  J Nucl Med       Date:  1997-05       Impact factor: 10.057

3.  Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.

Authors:  P Lind; H J Gallowitsch; W Langsteger; E Kresnik; P Mikosch; I Gomez
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.